Exact Mass: 702.426

Exact Mass Matches: 702.426

Found 215 metabolites which its exact mass value is equals to given mass value 702.426, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PA(13:0/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(13:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/PGE2), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/13:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(PGE2/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/13:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(13:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/PGD2), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/13:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(PGD2/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/13:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-(tridecanoyloxy)-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/13:0)

[(2R)-2-(tridecanoyloxy)-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/13:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H67O10P (702.4472)


PA(14:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H67O10P (702.4472)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(P-16:0/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-(hexadec-1-en-1-yloxy)propoxy]phosphonic acid

C37H67O10P (702.4472)


PA(P-16:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(P-16:0/5-iso PGF2VI), in particular, consists of one chain of one 1Z-hexadecenyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/P-16:0)

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-(hexadec-1-en-1-yloxy)propoxy]phosphonic acid

C37H67O10P (702.4472)


PA(5-iso PGF2VI/P-16:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/P-16:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 1Z-hexadecenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(a-13:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/PGE2), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/a-13:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(PGE2/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/a-13:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(a-13:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/PGD2), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/a-13:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(PGD2/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/a-13:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-[(10-methyldodecanoyl)oxy]-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(a-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/a-13:0)

[(2R)-2-[(10-methyldodecanoyl)oxy]-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/a-13:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(i-13:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/PGE2), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/i-13:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(PGE2/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/i-13:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(i-13:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/PGD2), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/i-13:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(PGD2/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/i-13:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-[(11-methyldodecanoyl)oxy]-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(i-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-13:0)

[(2R)-2-[(11-methyldodecanoyl)oxy]-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C36H63O11P (702.4108)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-13:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H67O10P (702.4472)


PA(i-14:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-14:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H67O10P (702.4472)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-14:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Kulomoopunalide-2

Kulomoopunalide-2

C38H62N4O8 (702.4567)


   

GERI 155

10,11-Dihydro-chalcomycin

C35H58O14 (702.3826)


   
   

brevenal dimethyl acetal

brevenal dimethyl acetal

C41H66O9 (702.4707)


   

3-Suberoylarginine ester -(3beta,5beta,11alpha,14beta)-3,5,14-Trihydroxycard-20(22)-enolide

3-Suberoylarginine ester -(3beta,5beta,11alpha,14beta)-3,5,14-Trihydroxycard-20(22)-enolide

C37H58N4O9 (702.4204)


   

3-O-(2,4-Diacetyl-beta-D-xylopyranoside)--16,23:16,24-Diepoxycycloart-7-ene-3,15,25-triol

3-O-(2,4-Diacetyl-beta-D-xylopyranoside)--16,23:16,24-Diepoxycycloart-7-ene-3,15,25-triol

C39H58O11 (702.3979)


   

2-deoxy-vobtusine|2-Desoxyvobtusin|Deoxyvobtusin|deoxyvobtusine|dihydroanhydrovobtusine|ent-6beta,21;6beta,21-diepoxy-17-methoxy-2,3-didehydro-(7betaC4,3beta)-3,4-dihydro-2H-spiro[aspidospermidine-7,5-pyrido[1,2,3:1,2,3]aspidospermidine]-3-carboxylic acid methyl ester

2-deoxy-vobtusine|2-Desoxyvobtusin|Deoxyvobtusin|deoxyvobtusine|dihydroanhydrovobtusine|ent-6beta,21;6beta,21-diepoxy-17-methoxy-2,3-didehydro-(7betaC4,3beta)-3,4-dihydro-2H-spiro[aspidospermidine-7,5-pyrido[1,2,3:1,2,3]aspidospermidine]-3-carboxylic acid methyl ester

C43H50N4O5 (702.3781)


   

reveromycin E 4-methyl ester

reveromycin E 4-methyl ester

C39H58O11 (702.3979)


   

23-O-diacetyl-7(8)-en-shengmanol-3-O-alpha?L-arabinopyranoside

23-O-diacetyl-7(8)-en-shengmanol-3-O-alpha?L-arabinopyranoside

C39H58O11 (702.3979)


   

Phlegmanol B-acetat

Phlegmanol B-acetat

C44H62O7 (702.4495)


   

3-O-acetyl-23-epi-26-deoxyactein

3-O-acetyl-23-epi-26-deoxyactein

C39H58O11 (702.3979)


   

2-O-Acetyl-27-deoxyactein

2-O-Acetyl-27-deoxyactein

C39H58O11 (702.3979)


   

spirangien A

spirangien A

C41H66O9 (702.4707)


   

Nilgherron B

Nilgherron B

C42H54O9 (702.3768)


   

PG(13:0/18:3(6Z,9Z,12Z))

1-tridecanoyl-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PG(13:0/18:3(9Z,12Z,15Z))

1-tridecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PG(14:1(9Z)/17:2(9Z,12Z))

1-(9Z-tetradecenoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PG(17:2(9Z,12Z)/14:1(9Z))

1-(9Z,12Z-heptadecadienoyl)-2-(9Z-tetradecenoyl)-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PG(18:3(6Z,9Z,12Z)/13:0)

1-(6Z,9Z,12Z-octadecatrienoyl)-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PG(18:3(9Z,12Z,15Z)/13:0)

1-(9Z,12Z,15Z-octadecatrienoyl)-2-tridecanoyl-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PG 31:3

1-(9Z,12Z-heptadecadienoyl)-2-(9Z-tetradecenoyl)-glycero-3-phospho-(1-sn-glycerol)

C37H67O10P (702.4472)


   

PA(a-13:0/PGE2)

PA(a-13:0/PGE2)

C36H63O11P (702.4108)


   

PA(PGE2/a-13:0)

PA(PGE2/a-13:0)

C36H63O11P (702.4108)


   

PA(a-13:0/PGD2)

PA(a-13:0/PGD2)

C36H63O11P (702.4108)


   

PA(PGD2/a-13:0)

PA(PGD2/a-13:0)

C36H63O11P (702.4108)


   

PA(i-13:0/PGE2)

PA(i-13:0/PGE2)

C36H63O11P (702.4108)


   

PA(PGE2/i-13:0)

PA(PGE2/i-13:0)

C36H63O11P (702.4108)


   

PA(i-13:0/PGD2)

PA(i-13:0/PGD2)

C36H63O11P (702.4108)


   

PA(PGD2/i-13:0)

PA(PGD2/i-13:0)

C36H63O11P (702.4108)


   
   
   
   
   

PA(14:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(14:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C37H67O10P (702.4472)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/14:0)

C37H67O10P (702.4472)


   

PA(i-14:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(i-14:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C37H67O10P (702.4472)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-14:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-14:0)

C37H67O10P (702.4472)


   

PA(13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C36H63O11P (702.4108)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/13:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/13:0)

C36H63O11P (702.4108)


   

PA(a-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(a-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C36H63O11P (702.4108)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/a-13:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/a-13:0)

C36H63O11P (702.4108)


   

PA(i-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(i-13:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C36H63O11P (702.4108)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-13:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-13:0)

C36H63O11P (702.4108)


   

PA(P-16:0/5-iso PGF2VI)

PA(P-16:0/5-iso PGF2VI)

C37H67O10P (702.4472)


   

PA(5-iso PGF2VI/P-16:0)

PA(5-iso PGF2VI/P-16:0)

C37H67O10P (702.4472)


   

Veraguamide D

Veraguamide D

C38H62N4O8 (702.4567)


A natural product found in Symploca hydnoides.

   

Dgdg O-18:4_2:0

Dgdg O-18:4_2:0

C35H58O14 (702.3826)


   

Mgdg O-28:7_4:0

Mgdg O-28:7_4:0

C41H66O9 (702.4707)


   

Mgdg O-26:7_6:0

Mgdg O-26:7_6:0

C41H66O9 (702.4707)


   

Dgdg O-16:4_4:0

Dgdg O-16:4_4:0

C35H58O14 (702.3826)


   

Mgdg O-16:4_16:3

Mgdg O-16:4_16:3

C41H66O9 (702.4707)


   

Mgdg O-16:3_16:4

Mgdg O-16:3_16:4

C41H66O9 (702.4707)


   

PE-Cer 20:3;2O/18:5

PE-Cer 20:3;2O/18:5

C40H67N2O6P (702.4736)


   

PE-Cer 16:3;2O/22:5

PE-Cer 16:3;2O/22:5

C40H67N2O6P (702.4736)


   

PE-Cer 14:2;2O/24:6

PE-Cer 14:2;2O/24:6

C40H67N2O6P (702.4736)


   

PE-Cer 18:3;2O/20:5

PE-Cer 18:3;2O/20:5

C40H67N2O6P (702.4736)


   

PE-Cer 12:1;2O/26:7

PE-Cer 12:1;2O/26:7

C40H67N2O6P (702.4736)


   

PE-Cer 14:3;2O/24:5

PE-Cer 14:3;2O/24:5

C40H67N2O6P (702.4736)


   

PE-Cer 16:2;2O/22:6

PE-Cer 16:2;2O/22:6

C40H67N2O6P (702.4736)


   

PE-Cer 12:2;2O/26:6

PE-Cer 12:2;2O/26:6

C40H67N2O6P (702.4736)


   

[(4E,8E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxytrideca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate

[(4E,8E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxytrideca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H67N2O6P (702.4736)


   

[(4E,8E,12E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]heptadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

[(4E,8E,12E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]heptadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H67N2O6P (702.4736)


   

[(4E,8E,12E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]pentadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

[(4E,8E,12E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]pentadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H67N2O6P (702.4736)


   

PMeOH 16:3_20:5

PMeOH 16:3_20:5

C40H63O8P (702.426)


   

PMeOH 18:4_18:4

PMeOH 18:4_18:4

C40H63O8P (702.426)


   

PMeOH 16:4_20:4

PMeOH 16:4_20:4

C40H63O8P (702.426)


   

PMeOH 18:3_18:5

PMeOH 18:3_18:5

C40H63O8P (702.426)


   

[(E)-2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxynon-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate

[(E)-2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxynon-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H67N2O6P (702.4736)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C37H67O10P (702.4472)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C37H67O10P (702.4472)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C37H67O10P (702.4472)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C37H67O10P (702.4472)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C37H67O10P (702.4472)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C37H67O10P (702.4472)


   

[1-[(9E,12E)-pentadeca-9,12-dienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[(9E,12E)-pentadeca-9,12-dienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C40H62O10 (702.4343)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C37H67O10P (702.4472)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C37H67O10P (702.4472)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoate

C40H63O8P (702.426)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate

C37H67O10P (702.4472)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C37H67O10P (702.4472)


   

[1-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C40H62O10 (702.4343)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C37H67O10P (702.4472)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C37H67O10P (702.4472)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C37H67O10P (702.4472)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E)-henicosa-9,11,13-trienoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E)-henicosa-9,11,13-trienoate

C40H63O8P (702.426)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoate

C40H63O8P (702.426)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C37H67O10P (702.4472)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C37H67O10P (702.4472)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tridecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C37H67O10P (702.4472)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C37H67O10P (702.4472)


   

2-[[3-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-dotriaconta-5,8,11,14,17,20,23,26,29-nonaenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-dotriaconta-5,8,11,14,17,20,23,26,29-nonaenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H65NO7P+ (702.4498)


   

phosphatidylserine 30:2(1-)

phosphatidylserine 30:2(1-)

C36H65NO10P (702.4346)


A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 30 carbons in total and 2 double bonds.

   
   

MGDG O-31:8;O

MGDG O-31:8;O

C40H62O10 (702.4343)


   

MGDG O-32:7

MGDG O-32:7

C41H66O9 (702.4707)


   
   
   
   
   
   
   

PA O-16:2/22:6

PA O-16:2/22:6

C41H67O7P (702.4624)


   
   

PA P-16:1/22:6

PA P-16:1/22:6

C41H67O7P (702.4624)


   

PA P-16:1/22:6 or PA O-16:2/22:6

PA P-16:1/22:6 or PA O-16:2/22:6

C41H67O7P (702.4624)


   
   

PA P-38:7 or PA O-38:8

PA P-38:7 or PA O-38:8

C41H67O7P (702.4624)


   

PA 14:0/20:3;O2

PA 14:0/20:3;O2

C37H67O10P (702.4472)


   

PA 16:1/18:2;O2

PA 16:1/18:2;O2

C37H67O10P (702.4472)


   

PA 22:0/12:3;O2

PA 22:0/12:3;O2

C37H67O10P (702.4472)


   

PA 22:1/11:3;O3

PA 22:1/11:3;O3

C36H63O11P (702.4108)


   

PA 22:1/12:2;O2

PA 22:1/12:2;O2

C37H67O10P (702.4472)


   
   
   
   
   
   
   

PG P-18:0/13:3;O

PG P-18:0/13:3;O

C37H67O10P (702.4472)


   

PG P-18:1/12:3;O2

PG P-18:1/12:3;O2

C36H63O11P (702.4108)


   

PG P-20:1/11:2;O

PG P-20:1/11:2;O

C37H67O10P (702.4472)


   
   
   
   
   
   
   
   
   
   
   
   
   

CerPE 16:2;O2/22:6

CerPE 16:2;O2/22:6

C40H67N2O6P (702.4736)


   
   

ST 29:1;O8;GlcA

ST 29:1;O8;GlcA

C35H58O14 (702.3826)


   

(2s)-n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-2-[(1-hydroxy-10-methylundecylidene)amino]butanediimidic acid

(2s)-n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-2-[(1-hydroxy-10-methylundecylidene)amino]butanediimidic acid

C36H54N4O10 (702.384)


   

(1r,4s,6s,9e,13s,14r,17s)-13-hydroxy-17-[({[(1r,4s,6s,9e,13s,14r,17s)-13-hydroxy-4,9,13-trimethyl-16-oxo-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-17-yl]methyl}sulfanyl)methyl]-4,9,13-trimethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-16-one

(1r,4s,6s,9e,13s,14r,17s)-13-hydroxy-17-[({[(1r,4s,6s,9e,13s,14r,17s)-13-hydroxy-4,9,13-trimethyl-16-oxo-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-17-yl]methyl}sulfanyl)methyl]-4,9,13-trimethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-16-one

C40H62O8S (702.4165)


   

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5r,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5r,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

13-hydroxy-17-{[({13-hydroxy-4,9,13-trimethyl-16-oxo-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-17-yl}methyl)sulfanyl]methyl}-4,9,13-trimethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-16-one

13-hydroxy-17-{[({13-hydroxy-4,9,13-trimethyl-16-oxo-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-17-yl}methyl)sulfanyl]methyl}-4,9,13-trimethyl-5,15-dioxatricyclo[12.3.1.0⁴,⁶]octadec-9-en-16-one

C40H62O8S (702.4165)


   

{2-[(8,11-dihydroxy-4,4,6a,6b,8a,11,12,14b-octamethyl-hexadecahydropicen-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

{2-[(8,11-dihydroxy-4,4,6a,6b,8a,11,12,14b-octamethyl-hexadecahydropicen-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxidanesulfonic acid

C36H62O11S (702.4013)


   

(4e,6e,8e,10e,12e)-15-hydroxy-16-{5-hydroxy-8-[(6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl}-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(4e,6e,8e,10e,12e)-15-hydroxy-16-{5-hydroxy-8-[(6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl}-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

8-(7,7-dimethoxy-4,5-dimethylhepta-3,5-dien-1-yl)-20-(hexa-3,5-dien-1-yl)-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosane-12,21-diol

8-(7,7-dimethoxy-4,5-dimethylhepta-3,5-dien-1-yl)-20-(hexa-3,5-dien-1-yl)-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosane-12,21-diol

C41H66O9 (702.4707)


   

3-{[4-(but-2-en-1-yloxy)-2-hydroxyphenyl]methyl}-9-{[4-(buta-2,3-dien-1-yloxy)phenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

3-{[4-(but-2-en-1-yloxy)-2-hydroxyphenyl]methyl}-9-{[4-(buta-2,3-dien-1-yloxy)phenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

C40H54N4O7 (702.3992)


   

2-amino-3-{[2-(9-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl)-1-hydroxyethyl]sulfanyl}propanoic acid

2-amino-3-{[2-(9-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl)-1-hydroxyethyl]sulfanyl}propanoic acid

C34H58N2O11S (702.3761)


   

16,23:16,24-diepoxycycloart-7-ene-3,15,25-triol; (3β,15α,23r,24r)-form,3-o-(2,4-diacetyl-beta-d-xylopyranoside)

NA

C39H58O11 (702.3979)


{"Ingredient_id": "HBIN001755","Ingredient_name": "16,23:16,24-diepoxycycloart-7-ene-3,15,25-triol; (3\u03b2,15\u03b1,23r,24r)-form,3-o-(2,4-diacetyl-beta-d-xylopyranoside)","Alias": "NA","Ingredient_formula": "C39H58O11","Ingredient_Smile": "NA","Ingredient_weight": "702.87","OB_score": "NA","CAS_id": "150972-75-1","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9286","PubChem_id": "NA","DrugBank_id": "NA"}

   

[(2r,3r,4s,5s,6r)-2-{[(3s,4ar,6ar,6br,8ar,11s,12s,12as,12br,14ar,14br)-11-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-hexadecahydropicen-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxidanesulfonic acid

[(2r,3r,4s,5s,6r)-2-{[(3s,4ar,6ar,6br,8ar,11s,12s,12as,12br,14ar,14br)-11-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-hexadecahydropicen-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxidanesulfonic acid

C36H62O11S (702.4013)


   

10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-hexyl-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

10-[8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-hexyl-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C39H58O11 (702.3979)


   

(1s,3r,5s,7s,8s,10r,12s,13s,15r,18s,20r,21r,24r)-8-[(3e,5e)-7,7-dimethoxy-4,5-dimethylhepta-3,5-dien-1-yl]-20-[(3z)-hexa-3,5-dien-1-yl]-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosane-12,21-diol

(1s,3r,5s,7s,8s,10r,12s,13s,15r,18s,20r,21r,24r)-8-[(3e,5e)-7,7-dimethoxy-4,5-dimethylhepta-3,5-dien-1-yl]-20-[(3z)-hexa-3,5-dien-1-yl]-7,10,15,21-tetramethyl-4,9,14,19,25-pentaoxapentacyclo[13.10.0.0³,¹³.0⁵,¹⁰.0¹⁸,²⁴]pentacosane-12,21-diol

C41H66O9 (702.4707)


   

18'-{[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

18'-{[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C39H58O11 (702.3979)


   

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-2-[(1-hydroxy-10-methylundecylidene)amino]butanediimidic acid

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-2-[(1-hydroxy-10-methylundecylidene)amino]butanediimidic acid

C36H54N4O10 (702.384)


   

2-amino-3-({2-[(14e)-9-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]-1-hydroxyethyl}sulfanyl)propanoic acid

2-amino-3-({2-[(14e)-9-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]-1-hydroxyethyl}sulfanyl)propanoic acid

C34H58N2O11S (702.3761)


   

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5r,6r,8r,9s,10r)-5-hydroxy-8-[(2r,3r,4r,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5r,6r,8r,9s,10r)-5-hydroxy-8-[(2r,3r,4r,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

(1r,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-(7,7-dimethyl-5,6-dioxooxepan-3-yl)-3b,6,6,9a,11a-pentamethyl-2-methylidene-1h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1r,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-(7,7-dimethyl-5,6-dioxooxepan-3-yl)-3b,6,6,9a,11a-pentamethyl-2-methylidene-1h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C42H54O9 (702.3768)


   

(3s,4z,6z,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(3s,4z,6z,8z,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

(2r)-2-amino-3-{[(1r)-2-[(1s,2s,3s,7s,8r,9s,10s,12r,14e,16r)-9-{[(2r,3r,4r,6s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]-1-hydroxyethyl]sulfanyl}propanoic acid

(2r)-2-amino-3-{[(1r)-2-[(1s,2s,3s,7s,8r,9s,10s,12r,14e,16r)-9-{[(2r,3r,4r,6s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]-1-hydroxyethyl]sulfanyl}propanoic acid

C34H58N2O11S (702.3761)


   

(3s,6r,7s,10s,13s,16s,21as)-3,16-bis[(2s)-butan-2-yl]-8-hydroxy-10,13-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13s,16s,21as)-3,16-bis[(2s)-butan-2-yl]-8-hydroxy-10,13-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C38H62N4O8 (702.4567)


   

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-3,15-dihydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethylnon-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(3s,4z,6e,8z,10e,12z,14s,15s,16s)-3,15-dihydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethylnon-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

methyl (11r,12'r,15s,24s,25r)-19-methoxy-8,15'-dioxa-4,8',17,19'-tetraazaspiro[heptacyclo[11.10.1.1¹,⁴.0⁷,¹¹.0¹⁷,²⁴.0¹⁸,²³.0¹¹,²⁵]pentacosane-15,17'-hexacyclo[10.9.1.0¹,⁹.0²,⁷.0¹²,¹⁶.0¹⁹,²²]docosane]-2',4',6',9',18,20,22-heptaene-10'-carboxylate

methyl (11r,12'r,15s,24s,25r)-19-methoxy-8,15'-dioxa-4,8',17,19'-tetraazaspiro[heptacyclo[11.10.1.1¹,⁴.0⁷,¹¹.0¹⁷,²⁴.0¹⁸,²³.0¹¹,²⁵]pentacosane-15,17'-hexacyclo[10.9.1.0¹,⁹.0²,⁷.0¹²,¹⁶.0¹⁹,²²]docosane]-2',4',6',9',18,20,22-heptaene-10'-carboxylate

C43H50N4O5 (702.3781)


   

(3s,6r,7s,10s,13s,16s,21as)-3,13-bis[(2s)-butan-2-yl]-8-hydroxy-10,16-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13s,16s,21as)-3,13-bis[(2s)-butan-2-yl]-8-hydroxy-10,16-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C38H62N4O8 (702.4567)


   

3,15-dihydroxy-16-[5-hydroxy-8-(3-hydroxy-4,6-dimethylnon-6-en-2-yl)-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

3,15-dihydroxy-16-[5-hydroxy-8-(3-hydroxy-4,6-dimethylnon-6-en-2-yl)-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

(4,5-dihydroxy-2-{[11-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-hexadecahydropicen-3-yl]oxy}-6-(hydroxymethyl)oxan-3-yl)oxidanesulfonic acid

(4,5-dihydroxy-2-{[11-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-hexadecahydropicen-3-yl]oxy}-6-(hydroxymethyl)oxan-3-yl)oxidanesulfonic acid

C36H62O11S (702.4013)


   

methyl (1'r,11r,12'r,15r,16's,22'r,24s,25r)-19-methoxy-8,15'-dioxa-4,8',17,19'-tetraazaspiro[heptacyclo[11.10.1.1¹,⁴.0⁷,¹¹.0¹⁷,²⁴.0¹⁸,²³.0¹¹,²⁵]pentacosane-15,17'-hexacyclo[10.9.1.0¹,⁹.0²,⁷.0¹²,¹⁶.0¹⁹,²²]docosane]-2',4',6',9',18,20,22-heptaene-10'-carboxylate

methyl (1'r,11r,12'r,15r,16's,22'r,24s,25r)-19-methoxy-8,15'-dioxa-4,8',17,19'-tetraazaspiro[heptacyclo[11.10.1.1¹,⁴.0⁷,¹¹.0¹⁷,²⁴.0¹⁸,²³.0¹¹,²⁵]pentacosane-15,17'-hexacyclo[10.9.1.0¹,⁹.0²,⁷.0¹²,¹⁶.0¹⁹,²²]docosane]-2',4',6',9',18,20,22-heptaene-10'-carboxylate

C43H50N4O5 (702.3781)


   

(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-hexyl-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-hexyl-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C39H58O11 (702.3979)


   

(3s,6s,9s,12s)-3-({4-[(2z)-but-2-en-1-yloxy]-2-hydroxyphenyl}methyl)-9-{[4-(buta-2,3-dien-1-yloxy)phenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

(3s,6s,9s,12s)-3-({4-[(2z)-but-2-en-1-yloxy]-2-hydroxyphenyl}methyl)-9-{[4-(buta-2,3-dien-1-yloxy)phenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

C40H54N4O7 (702.3992)


   

15-hydroxy-16-[5-hydroxy-8-(3-hydroxy-4,6-dimethyloct-6-en-2-yl)-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

15-hydroxy-16-[5-hydroxy-8-(3-hydroxy-4,6-dimethyloct-6-en-2-yl)-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

(1r,1'r,2s,3'r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-18'-{[(2s,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

(1r,1'r,2s,3'r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-18'-{[(2s,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C39H58O11 (702.3979)


   

[(2r,3r,4s,5s,6r)-2-{[(3s,4ar,6ar,6br,8s,8as,11s,12s,12as,12br,14ar,14br)-8,11-dihydroxy-4,4,6a,6b,8a,11,12,14b-octamethyl-hexadecahydropicen-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxidanesulfonic acid

[(2r,3r,4s,5s,6r)-2-{[(3s,4ar,6ar,6br,8s,8as,11s,12s,12as,12br,14ar,14br)-8,11-dihydroxy-4,4,6a,6b,8a,11,12,14b-octamethyl-hexadecahydropicen-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxidanesulfonic acid

C36H62O11S (702.4013)


   

(3s,6r,7s,10s,13r,16s,21as)-13-[(2r)-butan-2-yl]-3-[(2s)-butan-2-yl]-8-hydroxy-10,16-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13r,16s,21as)-13-[(2r)-butan-2-yl]-3-[(2s)-butan-2-yl]-8-hydroxy-10,16-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C38H62N4O8 (702.4567)


   

(1s,2r,3r,6z,8s,9s,10s,12s,16s)-12-hydroxy-2-{[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxy]methyl}-9-[(3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

(1s,2r,3r,6z,8s,9s,10s,12s,16s)-12-hydroxy-2-{[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxy]methyl}-9-[(3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

C35H58O14 (702.3826)


   

(3s,6s,9s,12s)-3-({4-[(2e)-but-2-en-1-yloxy]-2-hydroxyphenyl}methyl)-9-{[4-(buta-2,3-dien-1-yloxy)phenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

(3s,6s,9s,12s)-3-({4-[(2e)-but-2-en-1-yloxy]-2-hydroxyphenyl}methyl)-9-{[4-(buta-2,3-dien-1-yloxy)phenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

C40H54N4O7 (702.3992)


   

8-hydroxy-10,13-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3,16-bis(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

8-hydroxy-10,13-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3,16-bis(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C38H62N4O8 (702.4567)


   

(1s,2r,3r,6e,8s,9s,10s,12s,16s)-12-hydroxy-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(2s,3s,4r,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

(1s,2r,3r,6e,8s,9s,10s,12s,16s)-12-hydroxy-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(2s,3s,4r,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

C35H58O14 (702.3826)


   

(1r,2s,3s,6e,8r,9s,10r,12r,16r)-12-hydroxy-2-({[(2s,3s,4s,5s,6s)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(2r,3s,4r,6s)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

(1r,2s,3s,6e,8r,9s,10r,12r,16r)-12-hydroxy-2-({[(2s,3s,4s,5s,6s)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(2r,3s,4r,6s)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

C35H58O14 (702.3826)


   

(6e)-15-hydroxy-16-[5-hydroxy-8-(3-hydroxy-4,6-dimethyloct-6-en-2-yl)-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(6e)-15-hydroxy-16-[5-hydroxy-8-(3-hydroxy-4,6-dimethyloct-6-en-2-yl)-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)


   

8-hydroxy-10,16-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3,13-bis(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

8-hydroxy-10,16-diisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3,13-bis(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C38H62N4O8 (702.4567)


   

(3s,4e,6e,8e,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

(3s,4e,6e,8e,10e,12z,14s,15s,16s)-15-hydroxy-16-[(2s,3s,5s,6r,8r,9r,10r)-5-hydroxy-8-[(2r,3s,4s,6e)-3-hydroxy-4,6-dimethyloct-6-en-2-yl]-10-methoxy-3,9-dimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-3-methoxy-14-methylheptadeca-4,6,8,10,12-pentaenoic acid

C41H66O9 (702.4707)